Gilead Sciences, Inc. (GILD)
GILD stock forecast: what analysts expect
Wall Street analysts covering Gilead Sciences, Inc. currently rate the stock a Buy on average, with a mean 12-month price target of $157.41 — +15.9% versus the last price of $135.87. Targets reflect analyst opinion, not a guarantee.
GILD historical returns
Based on monthly dividend-adjusted prices. See the full breakdown on what if you had invested in GILD.
GILD annual returns by year
Congress trading in GILD
26 members of Congress have disclosed trading GILD — 25 purchases and 18 sales worth an estimated $658,000. Most recent disclosure: May 6, 2026.
See who in Congress traded GILD →Insider activity in GILD
GILD's own executives and directors have made 0 open-market purchases ($0) and 19 sales ($11.4M) in the last 90 days, per SEC Form 4 filings. Most recent: Aug 3, 2026.
| Aug 3, 2026 | O'Day Daniel Patrick | Chairman & CEO | Sell | $868,711 |
| Aug 3, 2026 | O'Day Daniel Patrick | Chairman & CEO | Sell | $1.0M |
| Aug 3, 2026 | O'Day Daniel Patrick | Chairman & CEO | Sell | $78,806 |
| Jul 15, 2026 | Dickinson Andrew D | Chief Financial Officer | Sell | $389,777 |
| Jul 15, 2026 | Mercier Johanna | Chief Comm & Corp Aff Officer | Sell | $389,758 |
About Gilead Sciences, Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
GILD Key Statistics
GILD in plain English
- ROE (-20.68%) — how efficiently the company turns shareholders' money into profit. Negative means it's currently losing money on that equity.
- Profit margin (-10.64%) — of every $1 in sales, this is what's left as profit after all costs.
- Dividend yield (2.42%) — the cash payout you'd earn per year as a % of the share price, on top of any price gains.
GILD stock: frequently asked questions
What is Gilead Sciences, Inc.'s stock price today?
Gilead Sciences, Inc. (GILD) last traded at $135.87 on the NASDAQ. Over the past 52 weeks the stock has traded between $108.46 and $157.29.
Is GILD stock a buy or a sell?
Wall Street analysts' consensus rating on GILD is "Buy", with an average 12-month price target of $157.41 — about +15.9% versus the current price of $135.87. Analyst targets are opinions, not guarantees; always do your own research.
How much would $1,000 invested in GILD 10 years ago be worth today?
A $1,000 investment in Gilead Sciences, Inc. made 10 years ago would be worth about $2,470 today (dividends reinvested) — a total return of 147%, or 9.5% per year.
Does GILD pay a dividend?
Yes. Gilead Sciences, Inc. currently pays a dividend yielding about 2.42% per year at today's share price.
Do members of Congress trade GILD stock?
Yes — 26 members of Congress have disclosed trades in GILD under the STOCK Act, totaling 25 purchases and 18 sales worth an estimated $658,000.
What is Gilead Sciences, Inc.'s ticker symbol?
Gilead Sciences, Inc. trades under the ticker symbol GILD on the NASDAQ.
Compare GILD with peers
Data last refreshed from public sources. Figures may be delayed. Not investment advice.